Is the price fair?
What DXCM's price assumes
Dexcom trades at 35.3× earnings against 33.4× for the median Medical Devices name, more expensive than its own group.
35.3
Trailing P/E · Medical Devices median 33.4 · 1.06× the median: the market pays up for this one
- Price / sales
- 5.13
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.0%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; the business has delivered +44% a year over the last three.
Details›
- Price / book2026-Q1
- 8.36
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $1.41B
- Market capitalisation
- $28.0B
- 3-year revenue growth
- +16%
- 3-year free cash flow growth
- +44%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 30.9× today against a 81.8× median |
| 52-week range | $54.84 – $92.34 |
| Today | $88.96 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #12 of 35 by Smart Score